

NHSBlood and Transplant

Education and Discussion GroupMeeting 55



RCI Assist – Sp-ICE up your life (OBOS having a good time)

This month we are joined by **Helen Thom**, **Pathology Business Development Manager**, **NHS Blood and Transplant**.

This meeting will start at 14:02 and will be recorded



Please use the Q&A function for all questions for the speaker



Please use the chat function for anything else



RCI Assist Sp-ICE up your life! (OBOS having a good time)

Helen Thom
Pathology BDM - NHSBT



RCI Assist





What is RCI Assist?

As part of the integrated transfusion services strategic plan for Transfusion 2024, a referral support tool, RCI Assist, has been developed.

RCI Assist guides users when processing samples in the Hospital Transfusion Laboratory (HTL). RCI Assist contains decision points to either refer cases to Red Cell Immunohaematology (RCI) or resolve in-house and is supported with pop up information to improve HTL staff confidence.


Pathways include:

- Grouping
- Antibody Identification
- Antenatal
- Panreactives
- Elution
- Transfusion



Scan here to see how to navigate RCI Assist





Accessing RCI Assist:



pitals & Sci Website RCI Assist is available as a link in Sp-ICE and OBOS

Log in with your usual credentials


Help Files - OBOS User Guide and Presentation | Component Portfolio | RCI Assist

For further information on RCI Assist, please visit the


NBTC website or email transfusion2024@nhsbt.nhs.uk

Case 1

- 65-year-old male
- Group & Screen
- No blood requested
- Pre-op assessment
- Historical alloanti-K
- Transfused 10 weeks ago
- LIMS and Sp-ICE results show patient as O+ E- K- with alloanti-K
- Previously seen by RCI


















Click to learn more


NO

Is ABO and D group interpretable?

Forward and reverse ABO groups match in accordance with Landsteiner's Law.

Note: Neonate groups are considered 'interpretable' from forward group only.

ABO forward group and D group show strong positive (3+/4+) reactions. Reverse group reactions may be weaker.



"For whichever ABO antigen is not present on the red cells, the corresponding antibody is found in the plasma"


"If you wanna be my donor, you better get with my antibodies"


















Is the ABO and D group interpretable?



Yes, no or unsure









Is the ABO and D group interpretable?

The forward and reverse ABO group match in accordance with Landsteiner's law and the D group shows strong positive reactions





RCI Assist Grouping Antibody ID Antenatal Panreactives Elutions Transfusion
























































Is the antibody screen positive?



Yes, no or unsure








Is the antibody screen positive?

Positive result obtained by IAT






Cell	Rh	D	C	Е	С	е	М	N	S	s	P1	K	k	Kpª	Leª	Le ^b	Fyª	Fyb	Jkª	Jkb	Other	IAT
1	R ₁ wR ₁	+	+	0	0	+	0	+	+	0	0	0	+	0	0	+	+	0	0	+		0
2	R_2R_2	+	0	+	+	0	+	0	0	+	0	0	+	0	+	0	0	+	+	0		1
3	rr	0	0	0	+	+	+	0	+	0	4	+	0	0	0	+	+	0	+	0		2































































Disclaimer: Read Here






Click to learn more

Check Patient History
Does patient have a known antibody?

Has this patient previously been tested and found to have red cell antibodies?



No blood requested

Pre-op assessment

Historical alloanti-K

Transfused 10 weeks ago


LIMS and Sp-ICE results show patient as O+ E- K- with alloanti-K

Previously seen by RCI

















































































































Case 1 – ABID Panel 1

Cell	Rh	D	С	E	С	е	М	N	S	s	P1	Lu ^a	к	k	Kpª	Leª	Le ^b	Fyª	Fyb	Jkª	Jkb	Other	IAT	ENZ
1	R ₁ wR ₁	+	+	0	0	+	0	+	0	+	1	0	0	+	0	+	0	+	0	+	0		+	(+)
2	R₁R₁	+	+	0	0	+	+	0	+	0	1	+	+	+	0	0	+	0	+	0	+		2	2
3	R_2R_2	+	0	+	+	0	0	+	0	+	0	0	0	+	0	0	+	+	w	0	+		0	0
4	r'r	0	+	0	+	+	0	+	+	0	4	0	0	+	0	0	+	0	+	+	+		0	0
5	r"r	0	0	+	+	+	+	0	+	0	3	0	0	+	0	0	+	0	+	+	0		(+)	+
6	rr	0	0	0	+	+	0	+	0	+	0	0	+	+	0	0	+	+	0	+	0	Do(a+b+)	2	2
7	rr	0	0	0	+	+	+	0	0	+	0	0	0	+	0	+	0	0	+	0	+		0	0
8	rr	0	0	0	+	+	0	+	0	+	2	0	0	+	+	+	0	0	+	+	0	HLA+	+	2
9	rr	0	0	0	+	+	0	+	+	0	3	0	0	+	0	+	0	+	0	0	+	Cob+ HLA+	0	0
10	rr	0	0	0	+	+	+	0	0	+	0	+	0	+	0	0	+	+	0	0	+		0	0
																						Auto	2	1
																						K control	2	I

























Panreactives

Elutions








RCI Assist









Antibody Inclusion/exclusion

- 6.2.4.Antibody specificity should only be assigned when the plasma is reactive with at least two examples of reagent red cells expressing the antigen and non-reactive with at least two examples of reagent red cells lacking the antigen
- 6.2.5.When one antibody specificity has been identified, it is essential that the presence or absence of additional clinically significant antibodies is established
- 6.2.6.Failure to recognise all of the antibody specificities within a sample may lead to a haemolytic transfusion reaction (SHOT, 1996–2010). In particular, the presence of anti-Jka, anti-Jkb, anti-S, anti-S, anti-Fya and anti-Fyb should be excluded using red cells having homozygous expression of the relevant antigen
- A single example only of each phenotype is sufficient for exclusion



Case 1 – ABID Panel 1

Cell	Rh	D/.	Æ	E/	1	×	Ŋ	N/	s/	*	P1/	Lu²	K	y /	Кра	Lor	Low	Fy	Fyt	Jka	Jk	Other	IAT	ENZ
1	R ₁ wR ₁	+	+	0	0	+	0	+	0	+	1	0	0	+	0	+	0	+	0	\odot	0		+	(+)
2	R ₁ R ₁	+	+	0	0	+	+	0	+	0	1	+	(·)	+	0	0	+	0	+	0	+		2	2
3	R ₂ R ₂	+	0	+	+	0	0	+	0	+	0	0	0	+	0	0	+	+	w	0	+		0	0
4	r'r	0	+	0	+	+	0	+	+	0	4	0	0	+	0	0	+	0	+	<u>+</u>	\bigcap		0	0
5	r"r	0	0	+	+	+	+	0	+	0	3	0	0	+	0	0	+	0	+	\odot	0		(+)	+
6	rr	0	0	0	+	+	0	+	0	+	0	0	\odot	+	0	0	+	+	0	\odot	0	Do(a+b+)	2	2
7	rr	0	0	0	+	+	+	0	0	+	0	0	0	+	0	+	0	0	+	0	+		0	0
8	rr	0	0	0	+	+	0	+	0	+	2	0	0	+	+	+	0	0	+	\odot	0	HLA+	+	2
9	rr	0	0	0	+	+	0	+	+	0	3	0	0	+	0	+	0	+	0	0	+	Cob+ HLA+	0	0
10	rr	0	0	0	+	+	+	0	0	† [0	Probable anti-K, anti-Jk ^a									1 +		0	0
												Have					Auto	2	1					
												Have not excluded anti-Kp ^a and C ^w										K control	2	1



What would really, really, really, really, wanna do next?





Zig a zig ah, good suggestions!







Screen

Cell	Rh	D	С	E	С	е	М	N	s	s	P1	K	k	Kpa	Leª	Le ^b	Fyª	Fyb	Jka	Jkb	Other	IAT
1	R ₁ ^w R ₁	+	+	0	0	+	0	+	+	0	0	0	+	0	0	+	+	0	0	+		0
2	R ₂ R ₂	+	0	+	+	0	+	0	0	+	0	0	+	0	+	0	0	+	(t)	0		1
3	rr	0	0	0	+	+	+	0	+	0	4	(0	0	0	+	+	0	\odot	0		2




Are anti-Kp^a and anti-C^w clinically significant antibodies in Transfusion?

Yes, no or unsure









BS	H Guidelines – clinical significa	nce of red cell antibodie	S
System	Specificity	Likely clinical transfusion	significance in
Kell	Anti-K	Yes	
Kidd	Anti-Jk ^a	Yes	
Rh	Anti-C ^w	No	15
Kell	Anti-Kp ^a	No	





When 2 become 1 (in RCI)

"The first time an antibody is detected, specificity is confirmed using 2 antigen positive cells, however on subsequent referrals a single antigen positive cell is sufficient to confirm the specificity of a previously reported antibody".

"If exclusion is not possible then the report must indicate those specificities that are not excluded. It is not necessary to exclude anti-N, -P1, -Lea, -Leb, -Cw, - Lua or - Kpa"

For HTL staff, follow your local procedures



Case 1 – ABID Panel 1


Cell	Rh	₽/.	Æ	E/	9	J.	14	N/	s/	*	P1/	Luª	K	y	Kpa	Lei	Lay	Fy	Fy	Jka	Jkb	Other	IAT	ENZ
1	R ₁ ^w R ₁	+	+	0	0	+	0	+	0	+	1	0	0	+	0	+	0	+	0	\odot	0		+	(+)
2	R₁R₁	+	+	0	0	+	+	0	+	0			(·)	+	0	0	+	0	+	0	+		2	2
3	R ₂ R ₂	+	0	+	+	0	0	+	0	+	0	0	0	+	0	0	+	+	w	0	+		0	0
4	r'r	0	+	0	+	+	0	+	+	0	4	0	0	+	0	0	+	0	+	Ť	$\overline{\cdot}$		0	0
5	r"r	0	0	+	+	+	+	0	+	0	3	0	0	+	0	0	+	0	+	\odot	0		(+)	+
6	rr	0	0	0	+	+	0	+	0	+	0	0	$\overline{\mathbf{\cdot}}$	+	0	0	+	+	0	\odot	0	Do(a+b+)	2	2
7	rr	0	0	0	+	+	+	0	0	+			0	+	0	+	0	0	+	0	+		0	0
8	rr	0	0	0	+	+	0	+	0	+	2	0	0	+	$\left(\cdot \right)$	+	0	0	+	\odot	0	HLA+	+	2
9	rr	0	0	0	+	+	0	+	+	0	3	0	0	+	0	+	0	+	0	0	+	Cob+ HLA+	0	0
10	rr	0	0	0	+	+	+	0	0	+	0	+	0	+	0	0	+	+	0	0	+		0	0
																						Auto	2	1
																						K control	2	1

Case 1 – ABID Panel 1

Cell	Rh	₽/.	Æ	E/	9	J.	M	N/	s/	*	P1/	Lu²	K	y	Kpa	Lei	Log	Fy	Fyt	Jka	Jkb	Other	IAT	ENZ
1	R ₁ ^w R ₁	+	+	0	0	+	0	+	0	+	1	0	0	+	0	+	0		—	\odot	0		+	(+)
2	R ₁ R ₁	+	+	0	0	+	+	0	+	0	1	+	(+)	+	0	0	+	0	+	0	+		2	2
3	R_2R_2	+	0	+	+	0	0	+	0	+	0	0	0	+	0	0	+	+	w	0	+		0	0
4	r'r	0	+	0	+	+	0	+	+	0	4	0	0	+	0	0	+	0	+	+	·		0	0
5	r"r	0	0	+	+	+	+	0	+	0	3	0	0	+	0	0	+			$\dot{\odot}$	0		(+)	+
6	rr	0	0	0	+	+	0	+	0	+	0	0	$\overline{\mathbf{\cdot}}$	+	0	0	+	+	0	\odot	0	Do(a+b+)	2	2
7	rr	0	0	0	+	+	+	0	0	+	0	0	0	+	0	+	0	0	+	0	+		0	0
8	rr	0	0	0	+	+	0	+	0	+	2	0	0	+	\odot	+	0	0	+	\odot	0	HLA+	+	2
9	rr	0	0	0	+	+	0	+	+	0	3	0	0	+	0	+	0	+	0	0	+	Cob+ HLA+	0	0
10	rr	0	0	0	+	+	+	0	0	+	0	+	0	+	0	0	+	+	0	0	+		0	0
																						Auto	2	1
																						K control	2	ı

Case 1 – ABID Panel 1

Cell	Rh	D/	Æ	E/	1	Je .	N	N/	s/	*	P1/	Lu²	K	y	Kpª	Lei	Low	Fy	Fy	Jka	Jkb	Other	IAT	ENZ
1	R ₁ ^w R ₁	+	+	0	0	+	0	+	0	+	1	0	0	+	0	+	0	+	0	(·)	0		+	(+)
2	R₁R₁	+	+	0	0	+	+	0	+	0	1	+	$\overline{(}$	+	0	0	+	0	+	0	+		2	2
3	R ₂ R ₂	+	0	+	+	0	0	+	0	+	0	0	0	+	0	0	+	+	w	0	+		0	0
4	r'r	0	+	0	+	+	0	+	+	0	4	0	0	+	0	0	+		\Leftrightarrow	÷	$\overline{\cdot}$		0	0
5	r"r	0	0	+	+	+	+	0	+	0	3	0	0	+	0	0	+	0	+	\odot	0		(+)	+
6	rr	0	0	0	+	+	0	+	0	+		1	\odot	+	0	0	+		\Leftrightarrow	\odot	0	Do(a+b+)	2	2
7	rr	0	0	0	+	+	+	0	0	+	0	0	0	+	0	+	0	0	+	0	+		0	0
8	rr	0	0	0	+	+	0	+	0	+	2	o l			\bigodot	+	0			\odot	0	HLA+	+	2
9	rr	0	0	0	+	+	0	+	+	0	3	0	0	+	0	+	0	+	0	0	+	Cob+ HLA+	0	0
10	rr	0	0	0	+	+	+	0	0	+	0	+	0	+	0	0	+	+	0	0	+		0	0
																						Auto	2	1
																						K control	2	I



Panreactives

Elutions















65-year-old male

Group & Screen

No blood requested

Pre-op assessment

Historical alloanti-K

Transfused 10 weeks ago


LIMS and Sp-ICE results show patient as O+ E- K- with alloanti-K

Check Patient Results and History

- 1. Have antibod(ies) been identified?
- 2. Have additional clinically significant antibodies been excluded?
- 3. Is patient pregnant?
- 4. Has this previously been investigated by RCI?

Hints and tips – reading and interpreting antibody ID panels

- Know the clinical significance of antibodies (read BSH guidelines)
- Confirm antibodies as alloantibodies (antigen phenotyping)
- Don't forget antigen dosage of cells
- Remember which cells are destroyed by enzyme which is worth considering when you are doing exclusions
- Cold reactive alloantibodies may react by IAT (E.g. Lewis and M antibodies)
- Column Agglutination Technology (CAT) can be prone to non-specific reactions
- Sometimes enzyme pan-reactivity causes non-specific reactivity in IAT. In such cases, please ensure that you can exclude all clinically significant antibodies by IAT.


































Elutions

Panreactives









































































Add comment on patient history


- Known alloanti-K
- Not-specified anti-Jk^a perform phenotyping 3 months post transfusion
- (Anti-Kp^a not excluded)











Select here to view RCI General guidance on eluate testing Check Patient History
Has patient been transfused
in the last 6 weeks?

NO

YES







RCI Assist **Elutions Panreactives**

NO

Select here to view RCI General guidance on eluate testing

Check Patient History Has patient been transfused in the last 6 weeks?

65-year-old male Group & Screen No blood requested Pre-op assessment Historical alloanti-K Transfused 10 weeks ago LIMS and Sp-ICE results show patient as O+ E- K- with alloanti-K












Select here to view RCI General guidance on eluate testing











Select here to view RCI General guidance on eluate testing Check Patient History
Has patient been transfused
in the last 6 weeks?

YES

NO Go to Transfusion Section

Elutions







RCI Assist Panreactives Transfusion

Transfusion Required? NO









RCI Assist Grouping Antibody ID Antenatal Panreactives Elutions Transfusion

Transfusion Required?


65-year-old male Group & Screen No blood requested Pre-op assessment Historical alloanti-K Transfused 10 weeks ago LIMS and Sp-ICE results show patient as O+ E- K- with alloanti-K












NO










































Stop right now! I need somebody with a reset button















Would you like to reset?




Please note: This will remove all progress made in all sections (Grouping, Antibody ID, Antenatal, Panreactives, Elutions and Transfusion).

Yes


No

Case 2

- 75-year-old male
- Group & Screen
- 2 units RBC
- "Anaemia"
- Not previously seen by your lab
- Transfused at a different HTL 3 weeks ago
- Sp-ICE results show patient as A+ E- K- with no historical antibodies
- Previously seen by RCI



















Yes, the ABO and D group is interpretable

The forward and reverse ABO group match in accordance with Landsteiner's law and the D group shows strong positive reactions





RCI Assist Grouping Antibody ID Antenatal Panreactives Elutions Transfusion


























Is antibody screen positive?

YES








Yes, the antibody screen is positive


Positive result obtained by IAT





Cell	Rh	D	С	E	С	е	М	N	S	s	P1	К	k	Kpª	Leª	Le ^b	Fyª	Fyb	Jkª	Jkb	Other	IAT
1	R ₁ ^w R ₁	+	+	0	0	+	+	0	+	0	0	0	+	0	0	+	+	0	0	+		1
2	R ₂ R ₂	+	0	+	+	0	0	+	0	+	0	0	+	0	+	0	0	+	+	0		1
3	rr	0	0	0	+	+	+	0	+	0	4	+	0	0	0	+	+	0	+	0		2













RCI Assist Antibody ID **Panreactives Elutions**















































Cell	Rh	D	С	E	С	е	М	N	s	s	P1	Lu ^a	К	k	Кра	Leª	Le ^b	Fyª	Fyb	Jkª	Jkb	Other	IAT	ENZ
1	R ₁ wR ₁	+	+	0	0	+	0	+	0	+	0	0	0	+	0	+	0	0	+	0	+		0	0
2	R ₁ R ₁	+	+	0	0	+	+	0	+	0	4	0	+	+	0	+	0	+	0	+	0		4	2
3	R ₂ R ₂	+	0	+	+	0	0	+	0	+	3	0	0	+	0	0	+	0	+	+	0	HLA+ Do(a+b+)	2	2
4	r'r	0	+	0	+	+	0	+	0	+	0	0	0	+	0	0	+	+	0	+	+		2	2
5	r"r	0	0	+	+	+	+	0	+	0	0	0	0	+	0	0	+	+	0	0	+		2	0
6	rr	0	0	0	+	+	+	0	0	+	2	0	+	0	0	0	+	0	+	0	+		0	0
7	rr	0	0	0	+	+	0	+	0	+	1	0	+	+	0	+	0	0	+	+	0		2	2
8	rr	0	0	0	+	+	+	0	0	+	0	0	0	+	+	0	+	+	0	0	+	Cob+	0	0
9	rr	0	0	0	+	+	0	+	+	0	4	0	0	+	0	0	+	0	+	0	+		3	0
10	rr	0	0	0	+	+	+	0	0	+	4	+	0	+	0	0	+	+	0	+	0	Cob+	2	2
																						Auto	3	1
																						K control	2	I





Elutions





Panreactives

Elutions







Cell	Rh	D/.	Æ	E/	4	ß	N/	z	s	*	P1/	Lua	K/	y	Ки	Ler	Low	Fy	Fyt	Jka	Jki	Other	IAT	ENZ
1	R ₁ wR ₁	+	+	0	0	+	0	+	0	+	0	0	0	+	0	+	0	0	+	0	+		0	0
2	R ₁ R ₁	+	+	0	0	+	+	0 (Ţ	0	4	0	+	+	0	+	0	+	0	\odot	0		4	2
3	R ₂ R ₂	+	0	+	+	0	0	+	0	+	3	0	0	+	0	0	+	0	+	\odot	0	HLA+ Do(a+b+)	2	2
4	r'r	0	+	0	+	+	0	+	0	+	0	0	0	+	0	0	+	+	0	\odot	+		2	2
5	r"r	0	0	+	+	+	+	0	·	0	0	0	0	+	0	0	+	+	0	0	+		2	0
6	rr	0	0	0	+	+	+	0	0	+	2	0	+	0	0	0	+	0	+	0	+		0	0
7	rr	0	0	0	+	+	0	+	0	+	1	0	+	+	0	+	0	0	+	$\overline{(\cdot)}$	0		2	2
8	rr	0	0	0	+	+	+	0	0	+	0	0	0	+	+	0	+	+	0	0	+	Cob+	0	0
9	rr	0	0	0	+	+	0	+ (·	0	4	0	0	+	0	0	+	0	+	0	+		3	0
10	rr	0	0	0	+	+	+	0	0	+	4	+	0	+	0	0	+	+	0	\odot	0	Cob+	2	2
													Dra	hah	le ar			Auto	3	I				
															t exc							K control	2	I





Is anti-Lu^a clinically significant in Transfusion?


Yes, no or unsure












System	Specificity	Likely clinical s transfusion	ignificance in
MNS	Anti-S	Yes	56
Kidd	Anti-Jk ^a	Yes	
Lu	Anti-Lu ^a	No	

Cell	Rh	D/	Æ	E/	9	Je de la constantina della con	M	N/(S	ø	P1/	Luª	K/	y	Ку	Lei	Lay	Fy	Fy	Jka	Jkb	Other	IAT	ENZ
1	R ₁ ^w R ₁	+	+	0	0	+	0	+	0	+	0	0	0	+	0	+	0	0	+	0	+		0	0
2	R₁R₁	+	+	0	0	+	+	0 ((\cdot)	0	4	0	+	+	0	+	0	+	0	\odot	0		4	2
3	R ₂ R ₂	+	0	+	+	0	0	+	0	+	3	0	0	+	0	0	+	0	+	\odot	0	HLA+ Do(a+b+)	2	2
4	r'r	0	+	0	+	+	0	+	0	+	0	0	0	+	0	0	+	+	0	(\cdot)	+		2	2
5	r"r	0	0	+	+			• ((\cdot)	0	0	0	0	+	0	0	+	+	0	0	+	\longrightarrow	2	0
6	rr	0	0	0	+	+	+	0	0	+	2	0	+	0	0	0	+	0	+	0	+		0	0
7	rr	0	0	0	+	+	0	+	0	+	1	0	+	+	0	+	0	0	+	(+)	0		2	2
8	rr	0	0	0	+	+	+	0	0	+	0	0	0	+	+	0	+	+	0	0	+	Cob+	0	0
9	rr	0	0	0	+			• ((+)	0	4	0	0	+	0	0	+	0	+	0	+		3	0
10	rr	0	0	0	+	+	+	0	0	+	4	÷	0	+	0	0	+	+	0	\bigcirc	0	Cob+	2	2
																						Auto	3	1
																						K control	2	I

Cell	Rh	₽/.	Æ	E	4	Je .	N/	Z/	(s)	J.	P1/	Luª	K/	y	Ки	Lef	Lgy	Fy	Fyt	Jka	Jkb	Other	IAT	ENZ
1	R ₁ wR ₁	+	+	0	0	+	0	+	0	+	0	0	0	+	0	+	0	0	+	0	+		0	0
2	R ₁ R ₁	+	+	0	0	+	+	0 ((0	4	0	+	+	0	+	0	+	0	(·	0		4	2
3	R ₂ R ₂	+	0	+	+	0	0	+	0	+	3	0	0	+	0	0	+	ļ		\odot	0	Do(a+b+)	2	2
4	r'r	0	+	0	+	+	0	+	0	+	0	0	0	+	0	0	+	+	0	(\cdot)	+		2	2
5	r"r	0	0	+	+	+	+	0	Ţ	0	0	0	0	+	0	0	+	+	0	0	+		2	0
6	rr	0	0	0	+	+	+	0	0	+	2	0	+	0	0	0	+	0	+	0	+		0	0
7	rr	0	0	0	+	+	0	+	0	+	1	0	+	+	0	+	0			+	0		2	2
8	rr	0	0	0	+	+	+	0	0	+	0	0	0	+	+	0	+	+	0	0	+	Cob+	0	0
9	rr	0	0	0	+	+	0	+ ((+)	0	4	0	0	+	0	0	+	0	+	0	+		3	0
10	rr	0	0	0	+	+	+	0	0	+	4	+	0	+	0	0	+	+	0	÷	0	Cob+	2	2
																						Auto	3	I
																						K control	2	I

Cell	Rh	D/	Æ	E/	1	Je .	N/	N/(s	ø	P1/	Luª	K/	y	Ки	Lei	Log	Fy	Fyt	Jka	Jkb	Other	IAT	ENZ
1	R ₁ wR ₁	+	+	0	0	+	0	+	0	+	0	0	0	+	0	+	0	0	+	0	+		0	0
2	R₁R₁	+	+	0	0		X	((\cdot)	0	4	0	+	+	0	+	0		\Rightarrow	\odot	0		4	2
3	R ₂ R ₂	+	0	+	+	0	0	+	0	+	3	0	0	+	0	0	+	0	+	\odot	0	HLA+ Do(a+b+)	2	2
4	r'r	0	+	0	+	+	0	+	0	+	0	0	0	+	0	0	+	+	0	(\cdot)	+		2	2
5	r"r	0	0	+	+	+	+	٥ ((\cdot)	0	0	0	0	+	0	0	+	+	0	0	+		2	0
6	rr	0	0	0	+	+	+	0	0	+	2	0	+	0	0	0	+	0	+	0	+		0	0
7	rr	0	0	0	+	+	0	+	0	+	1	0	+	+	0	+	0	0	+	(+)	0		2	2
8	rr	0	0	0	+	+	+	0	0	+	0	0	0	+	+	0	+	+	0	0	+	Cob+	0	0
9	rr	0	0	0	+	+	0	+ ((\cdot)	0	4	0	0	+	0	0	+	0	+	0	+		3	0
10	rr	0	0	0	+	+	+	0	0		\Leftrightarrow	+	0	+	0	0	+		\Leftrightarrow	\odot	0	Cob+	2	2
																						Auto	3	1
																						K control	2	I






Panreactives


Elutions


















Add comment on patient history

- Not-specified anti-S
- Not-specified anti-Jk^a
- Perform phenotyping 3 months post transfusion
- (Anti-Lu^a not excluded)









Check Patient History
Has patient been transfused
in the last 6 weeks?

NO

YES












Check Patient History
Has patient been transfused
in the last 6 weeks?

NO


YES
































A positive auto when a patient has been transfused in the last 6 weeks can indicate the sensitisation of donor red cells, and therefore the formation of new alloantibodies with the potential to cause transfusion reactions. Please note that if the auto control is negative and the patient has haemolysis, it is advisable perform an eluate in the absence of a positive DAT/ Auto. Elution should be undertaken if the clinical signs indicate a suspicion of a Haemolytic Transfusion Reaction (HTR).












Is the auto control positive?

	Cell	Rh	D	С	E	С	е	М	N	s	s	P1	Lua	κ	k	Kpª	Lea	Le ^b	Fyª	Fy ^b	Jka	Jkb	Other	IAT	ENZ
	1	R ₁ wR ₁	+	+	0	0	+	0	+	0	+	0	0	0	+	0	+	0	0	+	0	+		0	0
	2	R₁R₁	+	+	0	0	+	+	0	+	0	4	0	+	+	0	+	0	+	0	+	0		4	2
	3	R ₂ R ₂	+	0	+	+	0	0	+	0	+	3	0	0	+	0	0	+	0	+	+	0	HLA+ Do(a+b+)	2	2
	4	r'r	0	+	0	+	+	0	+	0	+	0	0	0	+	0	0	+	+	0	+	+		2	2
	5	r"r	0	0	+	+	+	+	0	+	0	0	0	0	+	0	0	+	+	0	0	+		2	0
	6	rr	0	0	0	+	+	+	0	0	+	2	0	+	0	0	0	+	0	+	0	+		0	0
	7	rr	0	0	0	+	+	0	+	0	+	1	0	+	+	0	+	0	0	+	+	0		2	2
	8	rr	0	0	0	+	+	+	0	0	+	0	0	0	+	+	0	+	+	0	0	+	Cob+	0	0
2/	9	rr	0	0	0	+	+	0	+	+	0	4	0	0	+	0	0	+	0	+	0	+		3	0
H	10	rr	0	0	0	+	+	+	0	0	+	4	+	0	+	0	0	+	+	0	+	0	Cob+	2	2
4																_							Auto	3	1
4																							K control	2	1
























Is the DAT IgG positive?

DAT profile	Anti-IgG	Anti-lgA	IgM	C3c	C3d	Ctrl
Result	3	0	0	0	0	0








Goodbye, my sample




Case 3

- 54-year-old male
- Group & Screen
- No blood requested
- RTA
- Not previously seen by your lab
- No record on Sp-ICE
- Not previously seen by RCI
- Never been transfused


















Is the ABO and D group interpretable?



Yes, no or unsure









Is the ABO and D group interpretable?

The forward and reverse ABO group **do not** match in accordance with Landsteiner's law





























A previous transfusion is the most likely source of an anomaly with the ABO or D group. Consider any type of transfusion (red cells, platelets, FFP, IvIg).

Dual populations arise in the case of red cell transfusion (ABO and/or D group not identical), whilst unexpected reactions may occur in the reverse group following transfusion with products containing plasma.


















? Help

















RCI Assist Grouping **Panreactives Elutions**














































Any thoughts on what it might Wanna-be?






Zig a zig ah, good suggestions!
























Yes, the antibody screen is positive






Positive result obtained by IAT





Cell	Rh	D	С	E	С	е	М	N	S	s	P1	К	k	Kpª	Leª	Le ^b	Fyª	Fyb	Jkª	Jkb	Other	IAT
1	R ₁ ^w R ₁	+	+	0	0	+	0	+	+	0	0	0	+	0	0	+	+	0	0	+		0
2	R_2R_2	+	0	+	+	0	+	0	+	0	0	0	+	0	+	0	0	+	+	0		0
3	rr	0	0	0	+	+	+	0	+	0	4	+	0	0	0	+	+	0	+	0		+/-

















































Has a pan-reactive antibody been identified by IAT?

NO


Case 3 – ABID Panel 1

Cell	Rh	D	С	E	С	е	М	N	s	s	P1	Lu ^a	к	k	Kpª	Leª	Le ^b	Fyª	Fy⁵	Jk ^a	Jkb	Other	IAT	ENZ
1	R ₁ wR ₁	+	+	0	0	+	+	0	+	0	3	0	+	0	0	0	+	0	+	0	+		1	0
2	R ₁ R ₁	+	+	0	0	+	+	+	0	+	1	0	0	+	0	+	0	+	0	+	0	HLA+	0	0
3	R ₂ R ₂	+	0	+	+	0	0	+	0	+	3	0	0	+	0	+	0	0	+	+	0		0	0
4	r'r	0	+	0	+	+	0	+	0	+	0	0	0	+	0	+	0	+	0	0	+		0	0
5	r"r	0	0	+	+	+	+	0	+	0	1	0	0	+	0	0	+	+	0	0	+		0	0
6	rr	0	0	0	+	+	0	+	0	+	4	0	+	0	0	0	+	0	+	+	0	HLA+	0	0
7	rr	0	0	0	+	+	0	+	0	+	0	0	+	+	0	0	+	w	0	+	0		0	0
8	rr	0	0	0	+	+	+	0	0	+	0	0	0	+	+	0	+	+	0	0	+		1	0
9	rr	0	0	0	+	+	0	+	+	0	1	0	0	+	0	0	+	+	0	+	0		0	0
10	rr	0	0	0	+	+	+	0	0	+	3	+	0	+	0	0	+	0	+	+	0		0	0
																						Auto	0	I
																						K control	2	I





Elutions





Panreactives

Elutions








Case 3 – ABID Panel 1

Cell	Rh	D	С	E	С	е	М	N	s	s	P1	Lu ^a	к	k	Крª	Leª	Le ^b	Fyª	Fyb	Jkª	Jk⁵	Other	IAT	ENZ
1	R ₁ wR ₁	+	+	0	0	+	+	0	+	0	3	0	+	0	0	0	+	0	+	0	+		1	0
2	R ₁ R ₁	+	+	0	0	+	+	+	0	+	1	0	0	+	0	+	0	+	0	+	0	HLA+	0	0
3	R ₂ R ₂	+	0	+	+	0	0	+	0	+	3	0	0	+	0	+	0	0	+	+	0		0	0
4	r'r	0	+	0	+	+	0	+	0	+	0	0	0	+	0	+	0	+	0	0	+		0	0
5	r"r	0	0	+	+	+	+	0	+	0	1	0	0	+	0	0	+	+	0	0	+		0	0
6	rr	0	0	0	+	+	0	+	0	+	4	0	+	0	0	0	+	0	+	+	0	HLA+	0	0
7	rr	0	0	0	+	+	0	+	0	+	0	0	+	+	0	0	+	w	0	+	0		0	0
8	rr	0	0	0	+	+	+	0	0	+	0	0	0	+	+	0	+	+	0	0	+		1	0
9	rr	0	0	0	+	+	0	+	+	0	1	0	0	+	0	0	+	+	0	+	0		0	0
10	rr	0	0	0	+	+	+	0	0	+	3	+	0	+	0	0	+	0	+	+	0		0	0
																						Auto	0	1
																						K control	2	1








What might you do if you suspect a cold antibody?

		_																						
Cell	Rh	D	С	E	С	е	М	N	s	s	P1	Lua	К	k	Kpª	Leª	Le ^b	Fyª	Fyb	Jkª	Jkb	Other	IAT	ENZ
1	R ₁ ^w R ₁	+	+	0	0	+	+	0	+	0	3	0	+	0	0	0	+	0	+	0	+		1	0
2	R ₁ R ₁	+	+	0	0	+	+	+	0	+	1	0	0	+	0	+	0	+	0	+	0	HLA+	0	0
3	R ₂ R ₂	+	0	+	+	0	0	+	0	+	3	0	0	+	0	+	0	0	+	+	0		0	0
4	r'r	0	+	0	+	+	0	+	0	+	0	0	0	+	0	+	0	+	0	0	+		0	0
5	r"r	0	0	+	+	+	+	0	+	0	1	0	0	+	0	0	+	+	0	0	+		0	0
6	rr	0	0	0	+	+	0	+	0	+	4	0	+	0	0	0	+	0	+	+	0	HLA+	0	0
7	rr	0	0	0	+	+	0	+	0	+	0	0	+	+	0	0	+	w	0	+	0		0	0
8	rr	0	0	0	+	+	+	0	0	+	0	0	0	+	+	0	+	+	0	0	+		1	0
9	rr	0	0	0	+	+	0	+	+	0	1	0	0	+	0	0	+	+	0	+	0		0	0
10	rr	0	0	0	+	+	+	0	0	+	3	+	0	+	0	0	+	0	+	+	0		0	0
																						Auto	0	1
																						K control	2	1







Zig a zig ah, good suggestions!



Case 3 – ABID 'cold' panel 1


Cell	Rh	D	С	E	С	е	М	N	s	s	P1	Lu ^a	к	k	Крª	Leª	Le ^b	Fyª	Fy⁵	Jkª	Jkb	Other	IAT	ENZ	Cold IAT
1	R ₁ wR ₁	+	+	0	0	+	+	0	+	0	3	0	+	0	0	0	+	0	+	0	+		1	0	2
2	R ₁ R ₁	+	+	0	0	+	+	+	0	+	1	0	0	+	0	+	0	+	0	+	0	HLA+	0	0	1
3	R ₂ R ₂	+	0	+	+	0	0	+	0	+	3	0	0	+	0	+	0	0	+	+	0		0	0	0
4	r'r	0	+	0	+	+	0	+	0	+	0	0	0	+	0	+	0	+	0	0	+		0	0	0
5	r"r	0	0	+	+	+	+	0	+	0	1	0	0	+	0	0	+	+	0	0	+		0	0	2
6	rr	0	0	0	+	+	0	+	0	+	4	0	+	0	0	0	+	0	+	+	0	HLA+	0	0	0
7	rr	0	0	0	+	+	0	+	0	+	0	0	+	+	0	0	+	w	0	+	0		0	0	0
8	rr	0	0	0	+	+	+	0	0	+	0	0	0	+	+	0	+	+	0	0	+		1	0	2
9	rr	0	0	0	+	+	0	+	+	0	1	0	0	+	0	0	+	+	0	+	0		0	0	0
10	rr	0	0	0	+	+	+	0	0	+	3	+	0	+	0	0	+	0	+	+	0		0	0	2
																						Auto	0	1	1
																						K control	2	1	1


Case 3 – ABID 'cold' panel 1

Cell	Rh	p/	£	E/	6/	9/	M	Ŋ	5/	\$/	P1/	Lyfa	y	/	Kp ^a	Lgfa .	Le ^b	Fyª	Fy ^b	/ska	jk♭	Other	IAT	ENZ	Cold IAT
1	R ₁ wR ₁	+	+	0	0	+	(†	0	+	0	3	0	+	0	0	0	+	0	+	0	+		1	0	2
2	R₁R₁	+	+	0	0	+	+	+	0	+	1	0	0	+	0	+	0	+	0	+	0	HLA+	0	0	1
3	R_2R_2	+	0	+	+	0	0	+	0	+	3	0	0	+	0	+	0	0	+	+	0		0	0	0
4	r'r	0	+	0	+	+	0	+	0	+	0	0	0	+	0	+	0	+	0	0	+		0	0	0
5	r"r	0	0	+	+	+	(†	0	+	0	1	0	0	+	0	0	+	+	0	0	+		0	0	2
6	rr	0	0	0	+	+	0	+	0	+	4	0	+	0	0	0	+	0	+	+	0	HLA+	0	0	0
7	rr	0	0	0	+	+	0	+	0	+	0	0	+	+	0	0	+	w	0	+	0		0	0	0
8	rr	0	0	0	+	+	+	0	0	+	0	0	0	+	+	0	+	+	0	0	+		1	0	2
9	rr	0	0	0	+	+	0	+	+	0	1	0	0	+	0	0	+	+	0	+	0		0	0	0
10	rr	0	0	0	+	+	(+)	0	0	+	3	+	0	+	0	0	+	0	+	+	0		0	0	2
																						Auto	0	I	1
																						K control	2	1	1




You could try and resolve group following local policies

































































NHS





Elutions








Case 3 – ABID 'cold' panel 1

Cell	Rh	D/	£	E/	6/	9	M	N/	5/	\$/	P1/	Lyfa	y	/	Kp ^a	Lgfa .	Le ^b	Fyª	/Fy ^b	ka	∫k ^b	Other	IAT	ENZ	Cold IAT
1	R ₁ wR ₁	+	+				+	0	+	0	3	0	+	0	0	0	+	0	+	0	+		1	0	2
2	R₁R₁	+	+	0	0	+	+	+	0	+	1	0	0	+	0	+	0	+	0	+	0	HLA+	•	•	1
3	R_2R_2	+	0	+	+	0	0	+	0	+	3	0	0	+	0	+	0	0	+	+	0		0	0	0
4	r'r	0	+	0	+	+	0	+	0	+	0	0	0	+	0	+	0	+	0	0	+		0	0	0
5	r"r	0	0	+	+	+	(+)	0	+	0	1	0	0	+	0	0	+	+	0	0	+		(°	(°	2
6	rr	0	0	0	+	+	0	+	0	+	4	0	+	0	0	0	+	0	+	+	0	HLA+	0	0	0
7	rr	0	0	0	+	+	0	+	0	+	0	0	+	+	0	0	+	w	0	+	0		0	0	0
8	rr	0	0				(+)	0	0	+	0	0	0	+	+	0	+	+	0	0	+		1	0	2
9	rr	0	0	0	+	+	0	+	+	0	1	0	0	+	0	0	+	+	0	+	0		0	0	0
10	rr	0	0	0	+	+	(+)	0	0	+	3	+	0	+	0	0	+	0	+	+	0		(°	(°	2
																						Auto	0	I	I
																						K control	2	ı	I





























Does your lab perform phenotyping? ('Common' antibodies)


- Do not perform any extended phenotyping (ABO/D only)
- Perform extended Rh/K but no additional typing
- Perform extended Rh/K and some additional typing
- Perform extended Rh/K and full additional typing








Mama, we stock you Mama, M negative Mama, alloanti-M



































Cancel




Is this Sp-ICE-ing up your life? OBOS having a good time?




Case 4

- 54-year-old female
- Group & Screen
- 2 units RBC
- PV bleed
- Not previously seen by your lab
- No record on Sp-ICE
- No historical antibodies
- Not previously seen by RCI



















Yes, the ABO and D group is interpretable

The forward and reverse ABO group match in accordance with Landsteiner's law and the D group shows strong positive reactions





RCI Assist Grouping Antibody ID Antenatal Panreactives Elutions Transfusion









































Yes, the antibody screen is positive


Positive result obtained by IAT





Cell	Rh	D	С	Е	С	е	М	N	Ø	s	P1	K	k	Kpª	Leª	Le ^b	Fyª	Fyb	Jkª	Jkb	Other	IAT
1	R ₁ ^w R ₁	+	+	0	0	+	0	+	+	0	0	0	+	0	0	+	0	+	0	+		0
2	R_2R_2	+	0	+	+	0	+	0	0	+	0	0	+	0	+	0	+	0	+	0		(+)
3	rr	0	0	0	+	+	+	0	+	0	4	+	0	0	0	+	+	0	0	+		+




















NHS


































Case 4 – ABID Panel 1

Cell	Rh	D	С	E	С	е	М	N	S	s	P1	Lu ^a	к	k	Kpª	Leª	Le ^b	Fyª	Fyb	Jkª	Jkb	Other	IAT	ENZ
1	R ₁ wR ₁	+	+	0	0	+	0	+	0	+	5	0	0	+	0	0	+	+	0	0	+		(+)	0
2	R₁R₁	+	+	0	0	+	+	0	+	0	4	0	+	+	0	0	+	0	+	+	0	HLA+	0	0
3	R ₂ R ₂	+	0	+	+	0	0	+	0	+	1	0	0	+	0	+	0	+	0	0	+	HLA+	(+)	2
4	r'r	0	+	0	+	+	0	+	0	+	0	0	0	+	0	+	0	+	0	0	+		(+)	0
5	r"r	0	0	+	+	+	+	0	+	0	2	0	0	+	0	0	+	0	+	+	0		0	2
6	rr	0	0	0	+	+	+	+	0	+	3	0	+	0	0	0	0	+	0	0	+		(+)	2
7	rr	0	0	0	+	+	0	+	0	+	0	0	+	+	0	0	+	+	0	+	0	Do(a+b+)	(+)	2
8	rr	0	0	0	+	+	+	0	0	+	0	0	0	+	+	0	+	0	+	0	+		0	2
9	rr	0	0	0	+	+	0	+	+	0	2	0	0	+	+	+	0	0	+	+	0	Cob+	0	2
10	rr	0	0	0	+	+	+	0	+	0	4	+	0	+	0	0	+	+	0	0	+	Kna-	(+)	2
																						Auto	0	1
																						K control	2	I





Elutions





Panreactives

Elutions







Case 4 – ABID Panel 1

Cell	Rh	D/		E	С	6/	M	Ŋ	4	1	P1/	Lu ^a	y	X	Koa	Lga	Le ^b	Fyª	уþ	ka	Ak _p	Other	IAT	ENZ
1	R ₁ wR ₁	+	+	0	0	+	0	+	0	+	5	0	0	1	0	0	<i>F</i>	+	0	0	+		(+)	0
2	R₁R₁	/ +	1	0	0	1	+/	0	7	0	/	0	1	+	0	0	+	0	/	<i>f</i>	0	HLA+	0	0
3	R ₂ R ₂	+	0	+	$\left(\begin{array}{c} + \end{array} \right)$) o	0	+	0	+	1	0	0	+	0	+	0	÷	0	0	+	HLA+	(+)	2
4	r'r	0	+	0	$\left(\cdot \right)$) +	0	+	0	+	0	0	0	+	0	+	0	\odot	0	0	+		(+)	$ \bigcirc $
5	r"r	0	0	+	()) +	+	0	+	0	2	0	0	+	0	0	+	0	+	+	0		0	2
6	rr	0	0	0	The state of the) +	+	+	0	+	3	0	+	0	0	0	0	·	0	0	+		(+)	2
7	rr	0	0	0	(\cdot)) +	0	+	0	+	0	0	+	+	0	0	+	\odot	0	+	0	Do(a+b+)	(+)	2
8	rr	0	0	0	+) +	+	0	0	1	0	0	0	+	+	0	+	0	+	0	1		0	2
9	rr	0	0	0	+) +	0	1	+	0	2	0	0	+	+	1	0	0	+	+	0	Cob+	0	2
10	rr	0	0	0	Ţ) +	+	0	+	0	4	+	0	+	0	0	+	÷	0	0	+	Kna-	(+)	2
									Probable anti-Fya and enzyme anti-c														0	1
									Ha	۲ ve n										i-E?))	K control	2	1

Case 4 – ABID Panel 1

equire at least two examples of reagent red ells expressing the antigen and non-reactive															Ko*	Lga	ye [∞]	Fyª	yν	ka	¥K₽	Other	IAT	ENZ
th at least two examples of reagent red cells cking the antigen														1	0	0	F	\odot	0	0	+		(+)	0
2 R ₁ R ₁ + + 0 0 + 0 + 0													1	+	0	0	+	0	/	<i>f</i>	0		0	0
3	R_2R_2	+	0	+ (Ť	0	0	+	0	+	1	0	0	+	0	+	0	(+)	0	0	+	HLA+	(+)	2
4	r'r	0	+	0	Ť) +	0	+	0	+	0	0	0	+	0	+	0	$\overline{\mathbf{+}}$	0	0	+		(+)	0
5	r"r	0	0	+	(+)) +	+	0	+	0	2	0	0	+	0	0	+	0	+	+	0		0	2
6	rr	0	0	0	Ť) +	+	+	0	+	3	0	+	0	0	0	0	\odot	0	0	+		(+)	2
7	rr	0	0	0	(†) +	0	+	0	+	0	0	+	+	0	0	+	\odot	0	+	0	Do(a+b+)	(+)	2
8	rr	0	0	0	(+) +	+	0	0	4	0	0	0	+	+	0	+	0	+	0	1		0	2
9	rr	0	0	0	Ť) +	0	/	+	0	2	0	0	+	/	/	0	0	+	+	0	Cob+	0	2
10	rr	0	0	0	Ť) +	+	0	+	0	4	+	0	+	0	0	+	\odot	0	0	+	Kna-	(+)	2
																						Auto	0	1
																						K control	2	1







54-year-old female

Group & Screen

2 units RBC

PV bleed

Not previously seen by your lab

No record on Sp-ICE

No historical antibodies


Not previously seen by RCI

Check Patient Results and History

- X 1. Have antibod(ies) been identified?
- 2. Have additional clinically significant antibodies been excluded?
- 3. Is patient pregnant?
- 4. Has this previously been investigated by RCI?

Hints and tips – reading and interpreting antibody ID panels

- Know the clinical significance of antibodies (read BSH guidelines)
- Confirm antibodies as alloantibodies (antigen phenotyping)
- Don't forget antigen dosage of cells
- Remember which cells are destroyed by enzyme which is worth considering when you are doing exclusions
- Cold reactive alloantibodies may react by IAT (E.g. Lewis and M antibodies)
- Column Agglutination Technology (CAT) can be prone to non-specific reactions
- Sometimes enzyme pan-reactivity causes non-specific reactivity in IAT. In such
 cases, please ensure that you can exclude all clinically significant antibodies by IAT.






Elutions














Elutions




















Case 4 – secondary panel

											_						_				_		_	
Cell	Rh	D	С	E	С	е	М	N	s	s	P1	Ju ^a	К	k	Kpª	Leª	Le ^b	Fyª	Fy ^b	Jkª	Jkb	Other	IAT	EIAT
1	R ₁ wR ₁	+	+	0	0	+	0	+	0	+	0	+	0	+	0	0	+	0	+	+	0		0	0
2	R₁R₁	+	+	0	0	+	+	0	+	0	1	0	+	+	0	0	+	+	0	0	+		(+)	0
3	R_2R_2	+	0	+ ($\left(\cdot \right)$	0	0	+	0	+	0	0	0	+	0	0	0	÷	0	0	+		(+)	2
4	r'r	0	+	0	(\cdot)	+	+	0	0	+	2	0	0	+	0	+	0		0	0	+		(+)	0
5	r"r	0	0	+ ((\cdot)	+	+	0	+	0	0	0	0	+	0	0	+	0	+	+	0		0	2
6	rr	0	0	0 (Ţ	+	+	+	0	+	4	0	+	0	0	0	+	()	0	+	0		(+)	2
7	rr	0	0	0	÷	+	0	+	0	+	1	0	+	+	0	+	0	0	+	+	0		0	2
8	rr	0	0	0 (+	+	+	0	+	0	0	0	0	+	+	0	0	0	+	0	+		0	2
9	rr	0	0	0 (÷	+	0	+	0	+	0	/	0	+	0	+	0	0	+	+	0		0	2
10	rr	0	0	0 ((\cdot)	+	0	+	+	0	3	0	0	+	0	0	0	÷	0	0	+		(+)	2
						Obta	aine	d s	ecc	ond p	os a	and r	neg to	o co	nfirm	ant	i-Fy ^a	and				Auto	1	1
					s	ecc	ond	ne	g fo	r ant	i-c. l	Have /me a	also	o exc			_					K control	2	1











Holler – do you want to do anything else?





Zig a zig ah, good suggestions!








No need to actively exclude anti-E enzyme

- 6.4.4.When an Rh antibody is suspected, the C, c, E, e types should be determined to aid in the selection of appropriately phenotyped red cells
- Check if patient has been recently transfused
- Referral to RCI would not resolve this. R1R1 panel (c-) is IAT only
- Could check the screening cells but they are IAT only


Cell	Rh	D	С	E	C	е	M	N	S	s	P1	K	k	Kpª	Leª	Le ^b	Fyª	Fy ^b	Jkª	Jk ^b	Other	IAT
1	R ₁ ^w R ₁	+	+	0	0	+	0	+	+	0	0	0	+	0	0	+	0	+	0	+		0
2	R_2R_2	+	0	+	+	0	+	0	0	+	0	0	+	0	+	0	(÷)	0	+	0		(+)
3	rr	0	0	0	+	+	+	0	+	0	4	+	0	0	0	+	+	0	0	+		+





















Disclaimer: Read Here



















Phenotyping results


- 6.4.4.When an Rh antibody is suspected, the C, c, E, e types should be determined to aid in the selection of appropriately phenotyped red cells
- This lab performs extended Rh/K and Duffy phenotyping
- Remember to check to see if the autocontrol is positive when using IgG antisera
- Patient is c- E- K- Fy(a)- negative and K negative
- Group on second sample confirmed the patient is A RhD+
- A R1R1 K- Fy(a-)











Panreactives Elutions Transfusion

Check Patient History

Has patient been transfused in the last 6 weeks?

YES

NO











RCI Assist Transfusion **Panreactives**
















RCI Assist Grouping Antibody ID Antenatal Panreactives Elutions Transfusion













RCI Assist Grouping Antibody ID Antenatal Panreactives Elutions Transfusion


























































What blood would you select?


- Group A D+ c- E- K- Fy(a-)
- Group A D+ c- K- Fy(a-)
- Group O D+ c- E- K- Fy(a-)
- Group O D+ c- K- Fy(a-)
- Not sure








Blood Selection




Unit 1: crossmatch compatible by IAT



Unit 2: not crossmatch compatible by IAT



















































Blood Selection



Unit 3: crossmatch compatible by IAT








































Hope that wasn't Too Much of something!



Case 5

- 90-year-old female
- Group & Screen
- No blood requested
- "On Dara"
- Extended phenotype results available on LIMS and Sp-ICE
- Known pan-reactive antibody due to monoclonal antibody therapy
- No alloantibodies
- DTT panel performed by RCI 2 weeks ago
- Never been transfused









Yes, the ABO and D group is interpretable

The forward and reverse ABO group match in accordance with Landsteiner's law and the D group shows strong positive reactions






























Is antibody screen positive?

YES








Yes, the antibody screen is positive


Positive result obtained by IAT





Cell	Rh	D	С	Е	С	е	М	N	S	s	P1	K	k	Kpª	Leª	Le ^b	Fyª	Fyb	Jkª	Jkb	Other	IAT
1	R ₁ ^w R ₁	+	+	0	0	+	0	+	+	0	0	0	+	0	0	+	0	+	0	+		1
2	R_2R_2	+	0	+	+	0	+	0	0	+	0	0	+	0	+	0	+	0	+	0		1
3	rr	0	0	0	+	+	+	0	+	0	4	+	0	0	0	+	+	0	+	0		1



























































































































































matching for all these antigens may not be desirable or achievable. Red cells should be matched for Rh and K as well as for any alloantibodies.











RCI Assist Panreactives **Elutions** Grouping





Extended phenotype

D	С	E	С	е	М	N	S	s	К	k _	Leª	Le ^b	Fyª	Fy ^b	Jkª	Jk ^b
+	+	-	+	+	-	+	+	+	-	+	+	+	+	+	+	-




































































































Panreactives


Elutions













Panreactives


Elutions













































Print page


Disclaimer: Read Here





























Stop right now! Thank you very much







Special thanks to...

Alex Hogan, Consultant Clinical Scientist Trainee (HSST)

Matt Bend, Blood Stock Management Scheme Manager

Gary Cavanagh, Pathology Business Development Manager

Sophie Hoyle, Digital Learning Developer

Staff at RCI Newcastle and Newcastle upon Tyne Hospitals NHS Foundation Trust

Staff at RCI Barnsley and Path Links Pathology Partnership

Staff at RCI Tooting and East and South-East London Pathology Partnership

All those that took the time to provide feedback

Transfusion 2024, RCI, HCS, DDTS and NHSBT Digital Learning Team



Blood Transfusion

Education and Discussion GroupMeeting 55



Thank you for listening!

Subscribe to our YouTube channel



Scan for course evaluation form



Antibody identification

[Session 3/3] The weird and the wonderful

DATE: 9th SEPT 2025 / 12:30PM



Registration

To register for this webinar, please click on the link <u>HERE</u> or scan the QR code on the right using your mobile device. A confirmation email with joining instructions will be sent to you automatically after successful registration.

Learning objectives [Session 3/3]

- 1. Introduction to high incidence antibodies
- Advanced techniques: alloadsorption, neutralisation, DTT treatment
- 3. Inhibition studies and their role in antibody ID
- 4. Case examples



Speaker:

Helen Thom

Biomedical scientist and RCI Development Lead -Transfusion 2024

NHSBT



Recording and certificate available for CPD purposes.